SGP
SpyGlass Pharma, Inc.
$19.52
+0.43 (+2.25%)
At close · Jul 7
Market Cap
$652.62M
Shares
33,433,355
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$39.87M
-36.7%
FY2025
Diluted EPS
-$17.98
-10.2%
FY2025
Operating Cash Flow
-$32.7M
-48.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 |
|---|---|---|
| $29.18M | $19.98M | |
| $12.27M | $7.08M | |
| $41.45M | $27.06M | |
| -$41.45M | -$27.06M | |
| $3.11M | $1.32M | |
| $1.58M | -$2.1M | |
| -$39.87M | -$29.16M | |
| $0 | $0 | |
| -$39.87M | -$29.16M | |
| -$39.87M | -$29.16M | |
| USD/shares | -$17.98 | -$16.31 |
| USD/shares | -$17.98 | -$16.31 |
| shares | 2.22M | 1.79M |
| shares | 2.22M | 1.79M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $1.45M in buybacks.